Global Blood Therapeutics Inc
NASDAQ:GBT
Income Statement
Earnings Waterfall
Global Blood Therapeutics Inc
Revenue
|
234.9m
USD
|
Cost of Revenue
|
-4.5m
USD
|
Gross Profit
|
230.4m
USD
|
Operating Expenses
|
-529.7m
USD
|
Operating Income
|
-299.2m
USD
|
Other Expenses
|
-23.2m
USD
|
Net Income
|
-322.5m
USD
|
Income Statement
Global Blood Therapeutics Inc
Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
16
+669%
|
48
+194%
|
85
+77%
|
124
+46%
|
149
+20%
|
165
+11%
|
180
+9%
|
195
+8%
|
211
+8%
|
235
+11%
|
|
Gross Profit | ||||||||||||||||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
16
+679%
|
47
+194%
|
84
+77%
|
122
+46%
|
146
+20%
|
162
+11%
|
177
+9%
|
191
+8%
|
207
+8%
|
230
+11%
|
|
Operating Income | ||||||||||||||||||||||||||||||||
Operating Expenses |
(21)
|
(23)
|
(27)
|
(36)
|
(46)
|
(56)
|
(65)
|
(71)
|
(83)
|
(90)
|
(97)
|
(105)
|
(119)
|
(138)
|
(156)
|
(173)
|
(183)
|
(193)
|
(211)
|
(234)
|
(292)
|
(318)
|
(341)
|
(367)
|
(366)
|
(387)
|
(417)
|
(441)
|
(479)
|
(497)
|
(530)
|
|
Selling, General & Administrative |
(4)
|
(5)
|
(5)
|
(7)
|
(10)
|
(13)
|
(16)
|
(19)
|
(22)
|
(24)
|
(26)
|
(28)
|
(31)
|
(38)
|
(43)
|
(47)
|
(51)
|
(57)
|
(71)
|
(88)
|
(117)
|
(147)
|
(171)
|
(196)
|
(211)
|
(222)
|
(234)
|
(248)
|
(267)
|
(283)
|
(303)
|
|
Research & Development |
(16)
|
(19)
|
(21)
|
(29)
|
(37)
|
(43)
|
(49)
|
(52)
|
(61)
|
(66)
|
(71)
|
(77)
|
(88)
|
(100)
|
(114)
|
(126)
|
(131)
|
(136)
|
(140)
|
(146)
|
(175)
|
(180)
|
(178)
|
(179)
|
(155)
|
(166)
|
(184)
|
(194)
|
(212)
|
(214)
|
(227)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
8
|
8
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(21)
N/A
|
(23)
-12%
|
(27)
-15%
|
(36)
-36%
|
(46)
-28%
|
(56)
-20%
|
(65)
-17%
|
(71)
-10%
|
(83)
-17%
|
(90)
-8%
|
(97)
-7%
|
(105)
-8%
|
(119)
-14%
|
(138)
-16%
|
(156)
-13%
|
(173)
-10%
|
(183)
-6%
|
(193)
-5%
|
(211)
-10%
|
(234)
-11%
|
(290)
-24%
|
(302)
-4%
|
(293)
+3%
|
(283)
+4%
|
(244)
+14%
|
(241)
+1%
|
(255)
-6%
|
(264)
-4%
|
(288)
-9%
|
(290)
-1%
|
(299)
-3%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||
Interest Income Expense |
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
3
|
3
|
5
|
6
|
9
|
11
|
13
|
14
|
15
|
12
|
7
|
2
|
(4)
|
(8)
|
(11)
|
(13)
|
(15)
|
(19)
|
(22)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Pre-Tax Income |
(21)
N/A
|
(23)
-11%
|
(27)
-15%
|
(36)
-36%
|
(46)
-28%
|
(56)
-20%
|
(65)
-16%
|
(71)
-10%
|
(82)
-16%
|
(89)
-8%
|
(95)
-7%
|
(103)
-8%
|
(117)
-14%
|
(135)
-16%
|
(152)
-12%
|
(166)
-10%
|
(174)
-5%
|
(182)
-4%
|
(199)
-9%
|
(220)
-11%
|
(267)
-21%
|
(291)
-9%
|
(286)
+2%
|
(282)
+2%
|
(248)
+12%
|
(249)
-1%
|
(266)
-7%
|
(277)
-4%
|
(303)
-9%
|
(309)
-2%
|
(322)
-4%
|
|
Net Income | ||||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
(1)
|
(1)
|
(1)
|
|
Income from Continuing Operations |
(21)
|
(23)
|
(27)
|
(36)
|
(46)
|
(56)
|
(65)
|
(71)
|
(82)
|
(89)
|
(95)
|
(103)
|
(117)
|
(135)
|
(152)
|
(166)
|
(174)
|
(182)
|
(199)
|
(220)
|
(267)
|
(291)
|
(286)
|
(282)
|
(248)
|
(249)
|
(266)
|
(277)
|
(303)
|
(310)
|
(322)
|
|
Net Income (Common) |
(21)
N/A
|
(23)
-11%
|
(27)
-15%
|
(36)
-36%
|
(46)
-28%
|
(56)
-20%
|
(65)
-16%
|
(71)
-10%
|
(82)
-16%
|
(89)
-8%
|
(95)
-7%
|
(103)
-8%
|
(117)
-14%
|
(135)
-16%
|
(152)
-12%
|
(166)
-10%
|
(174)
-5%
|
(182)
-4%
|
(199)
-9%
|
(220)
-11%
|
(267)
-21%
|
(291)
-9%
|
(286)
+2%
|
(282)
+2%
|
(248)
+12%
|
(249)
-1%
|
(266)
-7%
|
(277)
-4%
|
(303)
-9%
|
(310)
-2%
|
(322)
-4%
|
|
EPS (Diluted) |
-0.95
N/A
|
-1.06
-12%
|
-0.87
+18%
|
-2.09
-140%
|
-1.57
+25%
|
-1.89
-20%
|
-2.13
-13%
|
-1.95
+8%
|
-2.25
-15%
|
-2.28
-1%
|
-2.22
+3%
|
-2.38
-7%
|
-2.67
-12%
|
-2.83
-6%
|
-2.93
-4%
|
-3.19
-9%
|
-3.29
-3%
|
-3.23
+2%
|
-3.51
-9%
|
-3.66
-4%
|
-4.42
-21%
|
-4.78
-8%
|
-4.69
+2%
|
-4.58
+2%
|
-4
+13%
|
-4.02
0%
|
-4.27
-6%
|
-4.41
-3%
|
-4.7
-7%
|
-4.77
-1%
|
-4.92
-3%
|